In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 595-602

  Pillar, Chris M ^a   Aranza, Mohana K ^a   Shah, Dineshchandra ^a   Sahm, Daniel F ^a  

^a Eurofins Medinet Inc   (Germany)

Author keywords

Microbiology; MICs; Susceptibility tests

Indexed keywords

CEFEPIME; CEFTOBIPROLE; EXTENDED SPECTRUM BETA LACTAMASE;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 40049097830     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm492     Document Type: Article

References (25)

1. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 884-8.
2. Entenza JM, Hohl P, Heinze-Krauss I et al. BAL9141, a novel extended-spectrum, cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 2002; 46: 171-7.
3. Hebeisen P, Heinze-Krauss I, Angehm P et al. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-36.
4. Bogdanovich T, Ednie LM, Shapiro S et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49: 4210-9.
5. Deshpande L, Rhomberg PR, Fritsche TR et al. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis 2004; 50: 73-5.
6. Jones RN, Deshpande LM, Mutnick AH et al. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant stalphylococci. J Antimicrob Chemother 2002; 50: 915-32.
7. Issa NC, Rouse MS, Piper KE et al. In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria. Diagn Microbiol Infect Dis 2004; 48: 73-5.
8. Azoulay-Dupuis E, Bedos JP, Mohler J et al. Efficacy of BAL5788, a prodrug of cephalospodn BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother 2004; 48: 1105-11.
9. Murray PR, Baron EJ, Jorgensen JH et al. Manual of Clinical Microbiology. Washington, DC: ASM Press, 2007.
10. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
12. Livermore DM, Brown DF. Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48 Suppl 1: 59-64.
13. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 2006; 50 3959-62.
14. Deshpande LM, Jones RN. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin Microbiol Infect 2003; 9: 1120-4.
15. Heinze-Krauss I, Angehm P, Guerry P et al. Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci. J Med Chem 1996; 39: 1864-71.
16. Koga T, Abe T, Inoue H et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob Agents Chemother 2005; 49: 3239-50.
17. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
18. Ueda Y, Kanazawa K, Eguchi K et al. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 2005; 49: 4185-96.
19. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to β-lactams. Antimicrob Agents Chemother 2004; 48: 453-9.
20. Queenan AM, Bush K. Ceftobiprole: Effect on AmpC β-lactamase induction and resistance frequency in Gram-negative bacteria. In: Abstracts of the Forty-fifth Interscieece Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. American Society for Microbiology, Washington, DC, USA. Poster C1-55.
21. Sader HS, Hsiung A, Fritsche TR et al. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007; 57: 341-4.
22. Puerto AS, Fernandez JG, del Castillo Jde D et al. In vitro activity of β-lactam and non-β-lactam antibiotics in extended-spectrum β-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 2006; 54: 135-9.
23. Chanawong A, M'Zali FH, Heritage J et al. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Entembacteriaceae in the People's Republic of China. Antimicrob Agents Chemother 2002; 46: 630-7.
24. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
25. Munday CJ, Xiong J, Li C et al. Dissemination of CTX-M type β-lactamases in Enterobacteriaceae isolates in the People's Republic of China. Int J Antimicrob Agents 2004; 23: 175-80.